US2021128601A1PendingUtilityA1

Therapeutic agent for dry eye characterized by being applied to eye of dry eye patient wearing soft contact lens

Assignee: SANTEN PHARMACEUTICAL CO LTDPriority: Jun 5, 2015Filed: Jan 11, 2021Published: May 6, 2021
Est. expiryJun 5, 2035(~8.8 yrs left)· nominal 20-yr term from priority
A61P 27/04A61K 31/7084A61P 27/02A61K 47/18A61K 9/08A61K 9/0048A61K 47/10A61K 47/14A61K 31/7072A61K 31/155
62
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

An ophthalmic solution, which comprises diquafosol tetrasodium salt and is free from benzalkonium chloride, treats onset and/or exacerbation of dry eye symptom caused by wearing soft contact lenses.

Claims

exact text as granted — not AI-modified
1 . A therapeutic agent for dry eye characterized by being applied to an eye of a dry eye patient wearing soft contact lens, which comprises diquafosol or a salt thereof as an active ingredient and does not comprise benzalkonium chloride. 
     
     
         2 . The therapeutic agent according to  claim 1 , which is contained in a unit-dose type container. 
     
     
         3 . The therapeutic agent according to  claim 1 , which is contained in a multi-dose type container. 
     
     
         4 . The therapeutic agent according to  claim 3 , which comprises a preservative other than benzalkonium chloride. 
     
     
         5 . The therapeutic agent according to  claim 4 , wherein the preservative other than benzalkonium chloride is at least one selected from the group consisting of chlorhexidines, borates, chlorites, parabenes, sorbates, chlorobutanol and benzethonium chloride. 
     
     
         6 . The therapeutic agent according to  claim 4 , wherein the preservative other than benzalkonium chloride is chlorhexidines. 
     
     
         7 . The therapeutic agent according to  claim 1 , wherein a concentration of the diquafosol or a salt thereof is 0.5 to 5% (w/v). 
     
     
         8 . The therapeutic agent according to  claim 1 , wherein a concentration of the diquafosol or a salt thereof is 3% (w/v). 
     
     
         9 . The therapeutic agent according to  claim 1 , wherein the dry eye is caused by wearing contact lenses. 
     
     
         10 . An ophthalmic solution for improving tear film stability, characterized by being applied to an eye wearing a soft contact lens, which comprises diquafosol or a salt thereof as an active ingredient and does not comprise benzalkonium chloride. 
     
     
         11 . An ophthalmic solution for treating eye dryness or eye discomfort caused by wearing the soft contact lens, characterized by being applied to an eye wearing a soft contact lens, which comprises diquafosol or a salt thereof as an active ingredient and does not comprise benzalkonium chloride.

Join the waitlist — get patent alerts

Track US2021128601A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.